37675-19-7

Usage

Uses

Used in Pharmaceutical Research:
(R)-Piperidine-3-carboxylic acid ethyl ester hydrochloride is used as a reagent in pharmaceutical research for its ability to contribute to the synthesis of new pharmaceutical compounds. Its enhanced solubility and stability make it an ideal candidate for the development of drugs with improved properties.
Used in Organic Synthesis:
In the field of organic synthesis, (R)-Piperidine-3-carboxylic acid ethyl ester hydrochloride is used as a versatile building block for the creation of complex organic molecules. Its ethyl ester group and hydrochloride salt form provide the necessary stability and reactivity for various chemical reactions, facilitating the synthesis of a wide range of organic compounds.
Used in Drug Discovery:
(R)-Piperidine-3-carboxylic acid ethyl ester hydrochloride is employed as a key intermediate in drug discovery, where its unique structure and properties can be leveraged to design and develop novel therapeutic agents. (R)-Piperidine-3-carboxylic acid ethyl ester hydrochloride's enhanced stability and solubility make it a promising candidate for the creation of drugs with improved efficacy and safety profiles.
Used in Chemical Synthesis:
In chemical synthesis, (R)-Piperidine-3-carboxylic acid ethyl ester hydrochloride is used as a valuable precursor for the production of various chemical compounds. Its ethyl ester group and hydrochloride salt form provide the necessary reactivity and stability for use in a wide range of chemical reactions, making it a versatile component in the synthesis of diverse chemical products.

InChI:InChI=1/C8H15NO2.ClH/c1-2-11-8(10)7-4-3-5-9-6-7;/h7,9H,2-6H2,1H3;1H/t7-;/m1./s1

Upstream product

• 191599-51-6 ethyl (S)-1-[(tert-butoxy)carbonyl]piperidine-3-carboxylate 
• 37675-18-6 (S)-(+)-nipecotic acid ethyl ester 
• 64-17-5 ethanol 
• 88495-54-9 (3S)-1-(tert-butoxycarbonyl)piperidine-3-carboxylic acid 
• 614-18-6 3-pyridinecarboxylic acid ethyl ester 
• 148672-74-6 ethyl N-(t-butyloxycarbonyl)nipecotate 
• 498-95-3 nipecotic acid 
• 5166-67-6 ethyl 1-methylpiperidine-3-carboxylate 

Downstream Products

• 148672-74-6 ethyl N-(t-butyloxycarbonyl)nipecotate 

Relevant academic research and scientific papers

HMPA-catalyzed transfer hydrogenation of 3-carbonyl pyridines and other N-heteroarenes with trichlorosilane

A method for the HMPA (hexamethylphosphoric triamide)-catalyzed metal-freetransfer hydrogenation of pyridines has been developed. The functional group tolerance of the existing reaction conditions provides easy access to various piperidines with ester or ketone groups at the C-3 site. The suitability of this method for the reduction of other N-heteroarenes has also been demonstrated. Thirty-three examples of different substrates have been reduced to designed products with 45–96% yields.

SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF

Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.

JAK INHIBITOR

The present invention discloses a series of JAK inhibitors, and particularly discloses a compound of formula (I) or a pharmaceutically acceptable salt thereof and the use thereof in preparation of drugs for treating diseases related to JAK.

PROCESS FOR PREPARING ENANTIOMERICALLY ENRICHED 3-HYDROXYMETHYLPIPERIDINE

The present invention relates to a process for preparing enantiomerically enriched 3-hydroxymethylpiperidine and in particular of the S-enantiomer of (S)-3-hydroxymethyl- piperidine in high chemical and optical purity. The invention also relates to extremely pure (S)-3-hydroxymethylpiperidine and (R)-3-hydroxymethylpiperidine.

BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP)

A compound having the structure set forth in Formula (I) or Formula (II): wherein the variables Y, R1, R2, R3, and R4 are as defined herein. Provided herein are inhibitors of poly(ADP-ribose)polymerase activity. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat diseases, disorders and conditions that are ameliorated by the inhibition of PARP activity.

NOVEL INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP)

A compound having the structure set forth in Formula (I): wherein the variables Y, R1, R2, R3, R4 and R5 are as defined herein. Compounds described herein are inhibitors of poly(ADP-ribose)polymerase activity. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of such compounds and pharmaceutical compositions to treat diseases, disorders and conditions that are ameliorated by the inhibition of PARP activity

A General, Selective, High-Yield N-Demethylation Procedure for Tertiary Amines by Solid Reagents in a Convenient Column Chromatography-like Setup

(Equation presented) A traditional preparative chromatographic column can be used to achieve quantitative N-demethylation of tertiary N-methylamines and alkaloids. The filling is the crucial part and is loaded with different solid reagents in three reaction zones. The parent compound is charged on the column, and the neat N-demethylated secondary amine leaves the column some minutes later.

Oligomers of β2- and of β3-homoproline: What are the secondary structures of β-peptides lacking H-bonds?

To study the role of H-bonds in stabilizing β-peptidic secondary structures, we have synthesized β-oligopeptides (up to the octadecamer 12) consisting of β2- and β3-homoproline, i.e., β-peptides lacking amide protons. The enantiomer purity of the building block β2-homoproline (nipecotic acid, 4) was determined by HPLC analysis of the N-(2,4- dinitrophenyl) derivative 5 on a Chiralcel-OD column (cf. Fig. 2). The CD spectra of the all-(S)-β2- and all-(S)-β3-HPro-containing, β-peptides display novel and intensive CD patterns which may be indicative of a secondary structure (cf. Fig. 3). It is noteworthy that a distinct CD pattern was observed with the β3-HPro derivatives containing as few as three residues (7a). The crystal structure of a N-deprotected β3-HPro-tripeptide 7c is presented (cf. Figs. 4 and 5), and a model for the structure of β- peptides consisting of β3-HPro is discussed (cf. Figs. 6 and 7).